Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Senti Biosciences. The associated price target is $12.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Emily Bodnar has given his Buy rating due to a combination of factors related to SENTI-202’s early clinical performance and regulatory momentum. The Phase 1 trial in relapsed/refractory AML has shown a compelling overall response rate and complete response metrics, even in a more heavily pretreated and higher-risk patient cohort at the recommended Phase 2 dose, alongside meaningful MRD negativity and promising durability that may improve with longer follow‑up.
Regulatory signals also underpin the constructive view, as SENTI-202 has secured both RMAT and orphan drug status, which together support a streamlined, capital-efficient path to potential approval and enable frequent FDA dialogue ahead of a planned pivotal program. Bodnar expects upcoming FDA feedback on a likely single‑arm registrational study and additional durability data in 2026 to serve as key value inflection points, while acknowledging financing needs remain an overhang that could be mitigated if regulatory clarity catalyzes favorable capital access.
Bodnar covers the Healthcare sector, focusing on stocks such as NovoCure, Acrivon Therapeutics, Inc., and Agenus. According to TipRanks, Bodnar has an average return of 5.6% and a 33.68% success rate on recommended stocks.